Breast Cancer Foundation NZ
PET LABRADOR
Advanced Breast Cancer clinical trials for ER+
Recruiting
Updated: January 20, 2022
This study is assessing the benefits of prescribed exercise in clinical populations, including people with breast cancer.
This study uses PET scans for locally advanced breast cancer and diagnostic MRI to determine the extent of operation and radiotherapy.
Key inclusion criteria
- Cytological + / - Histological confirmation of disease within 28 days prior to registration
- Clinical Stage III (non-inflammatory) unilateral breast cancer
- Adequate haematological, renal and hepatic function as defined by:
- Absolute neutrophil count (ANC, segs + bands) > / =1.5 x 109 / L
- Platelet count > / = 100 x 109 / L
- Total Bilirubin > / = 1.5 x upper normal limit
- Alaninie aminotransferase (ALT) < / = 2.5 x upper normal limit
- EGFR >30ml/min
- Women must be suitable for radical treatment employing chemotherapy, surgery, radiation therapy + / - trastuzumab + / - hormonal therapy
- A ECOG performance status score of 1 or less within 28 days prior to registration
- No contraindications to receiving radiation treatment
- Life expectancy greater than 36 months
- Participants capable of childbearing are using adequate contraception.
- Available for follow up
Patients may proceed to protocol treatment if they meet the following criteria:
- 10. Adequate cardiac function as defined by a left ventricular ejection fraction of >50%, unless patient is enrolled on a study of primary endocrine therapy.
- 11. Patients who have no metasteses on PET CT scan OR PET-CT scan identifies up to 3 sites of metastases only.
Key exclusion criteria
- Women who are pregnant or lactating
- Women who are unwilling to have photographs taken of the area from the mid-neck to navel at specified time-points throughout the study.
- Women with implanted medical or electronic devices deemed by the MRI radiologist to be a contra-indication to performing a breast MRI, for example: implanted defibrillator, cardiac pacemaker, a cochlear implant, implanted drug infusion port, a metallic joint prosthesis, nerve stimulators, metal pins, screws, plates, stents or surgical staples
- Clinical evidence of bilateral breast cancer
- Previous RT to the area to be treated
- Previous chemotherapy
- Previous surgery to the ipsilateral breast or nodes
- Previous contralateral breast cancer
- Prior diagnosis of cancer with subsequent evidence of disease recurrence or clinical expectation of recurrence is greater than 10% within 5 years of current diagnosis with the exception of successfully treated basal cell or squamous cell skin carcinoma or carcinoma in situ of the cervix
- Patients with clinical evidence of metastatic disease
New Zealand
Auckland
Australia
If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Advanced Breast Cancer , DCIS
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.